Deutsche Bank Research has increased its price target for Bayer AG to 65 Euro from 60 Euro, maintaining a 'Buy' rating. This adjustment is based on updated EBITDA and EPS estimates for 2027 and 2028, driven by strong performance in Bayer's pharmaceutical business.
Deutsche Bank Research raised Bayer's price target to 65 Euro from 60 Euro, while reiterating a 'Buy' rating. This positive revision stems from updated financial estimates for 2027 and 2028, specifically improved EBITDA and earnings per share projections. The analyst highlighted the robust performance of Bayer's pharmaceutical division as the primary catalyst for this revised outlook. This news is moderately positive for Bayer, signaling analyst confidence in its future earnings potential, particularly in its core drug business. For traders, this could provide a short-term positive sentiment boost, but the long-term implications depend on the company's ability to meet or exceed these revised estimates.